Insulet (PODD) 44th Annual J.P. Morgan Healthcare Conference summary

Vision and Mission

• Focused on transforming diabetes care through innovation, empathy, and science, aiming to reduce the daily burden of diabetes globally.

Market Leadership and Growth

• Holds the top position in U.S. and EU for new customer starts and prescribed AID systems, with over 600,000 active customers across 25 global markets.

• Omnipod 5 is the most requested and prescribed AID system, leading new customer starts in the U.S. and Europe.

• Drove 66% of global AID market growth from 2020–2025, with market share in new customer starts growing from under 30% in 2020 to 50%.

• Revenue expected to reach $2.7 billion in 2025, with a 25% CAGR from 2021–2025 and expanding margins.

• Maintains deep competitive moats in technology, manufacturing, access, and brand loyalty.

Financial Performance and Guidance

• Achieved sustained revenue growth, expanding adjusted operating margin by ~600 bps and adjusted EPS by 54% CAGR from 2021–2025.

• Free cash flow increased by $510M over the same period.

• 2025 revenue guidance projects 28–29% constant currency growth, with international Omnipod growth outpacing U.S.

• Adjusted operating margin expected to expand by ~100 bps annually from 2025–2028.

• Forecasts 20% revenue growth through 2028, with 100 basis points of margin expansion per year.